Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-25

Study Completion Date

2024-12-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

To assess the incidence rate of dose-limiting toxicity and to confirm the recommended dose as well as the maximum tolerated dose of SAR439859 administered as monotherapy to Japanese postmenopausal women with estrogen receptor positive and human epidermal growth factor receptor 2-negative advanced breast cancer.

Secondary Objective:

* To characterize the overall safety profile of SAR439859 administered as monotherapy.
* To characterize the pharmacokinetic profile of SAR439859 administered as monotherapy.
* To evaluate the antitumor activity of SAR439859 administered as monotherapy and the clinical benefit rate (complete response, partial response and stable disease ≥ 24 weeks).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

NCT03284957

Breast Cancer

TERMINATED PHASE1/PHASE2

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

NCT05128773

Breast Cancer

TERMINATED PHASE3

Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

NCT04940026

Breast Cancer Healthy Volunteers

COMPLETED PHASE1

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00014638

Breast Cancer

COMPLETED PHASE4

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

NCT00237198

Postmenopausal Women With Advanced Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The duration of the study for an individual participant will include a period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1 cycle (28 days) of study treatment, and an End of Treatment (EOT) visit at least 30 days (or until the participant receives another anticancer therapy, whichever is earlier) following the last administration of study treatment. Study treatment may continue until precluded by unacceptable toxicity, disease progression, or upon participant's request.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAR439859

administered orally once daily or twice daily as monotherapy in fasted or fed state

Group Type EXPERIMENTAL

Amcenestrant (SAR439859)

Intervention Type DRUG

Pharmaceutical form: Capsules

Route of administration: Oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amcenestrant (SAR439859)

Pharmaceutical form: Capsules

Route of administration: Oral

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must be postmenopausal women.
* Breast adenocarcinoma patients with locally advanced not amenable to radiation or surgery, inoperable and/or metastatic disease.
* Either the primary or any metastatic site must be positive for estrogen receptor (ER) (\>1% staining by immunohistochemistry).
* Either the primary tumor or any metastatic site must be human epidermal growth factor receptor 2 non-overexpressing.
* Patients with at least 6 months of prior endocrine therapy.

Exclusion Criteria

* Eastern Cooperative Oncology Group Performance Status (ECOG) ≥2.
* Significant concomitant illness that would adversely affect participation in the study.
* Patients with a life expectancy less than 3 months.
* Patient not suitable for participation, whatever the reason.
* Major surgery within 4 weeks prior to first study treatment administration.
* Treatment with strong and moderate cytochrome P450 3A inhibitors/inducers.
* Patients with known endometrial disorders, uterine bleeding or ovarian cysts.
* Treatment with anticancer less than 2 weeks before first study treatment.
* Prior treatment with selective estrogen receptor down (SERD)-regulator (except fulvestrant for which a washout of at least 6 weeks is required).
* Inadequate hematological function.
* Inadequate renal function with serum creatinine ≥1.5 x upper limit of normal (ULN).
* Liver function: aspartate aminotransferase \>3 x ULN, or alanine aminotransferase \>3 x ULN. Total bilirubin \>1.5 x ULN.
* Non-resolution of any prior treatment related toxicity to \<Grade 2, except for alopecia

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No